about
Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patientsImpact of glutathione S-transferase M1 and T1 on anti-tuberculosis drug-induced hepatotoxicity in Chinese pediatric patientsFirst dose in neonates: are juvenile mice, adults and in vitro-in silico data predictive of neonatal pharmacokinetics of fluconazole.Determination of ciprofloxacin in plasma by micro-liquid chromatography-mass spectrometry: an adapted method for neonates.Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome.Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease.Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age.Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder.Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations?Cystatin C as a potential biomarker for dosing of renally excreted drugs.Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease.Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates.External Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: The transferability of published models to different clinical settings.Clinical Utility and Safety of a Model-Based Patient-Tailored Dose of Vancomycin in Neonates.A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young InfantsCovariate effects and population pharmacokinetics of lamivudine in HIV-infected children.Developmental pharmacogenetics of immunosuppressants in pediatric organ transplantation.Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration.How to use vancomycin optimally in neonates: remaining questions.Commentary on the MID3 Good Practices Paper.A model-based approach for the evaluation of once daily dosing of lamivudine in HIV-infected children.Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design.Safety study of Ciprofloxacin in newborn mice.Therapeutic guidelines for prescribing antibiotics in neonates should be evidence-based: a French national survey.Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring.Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients.Pharmacokinetics and dosage individualization of ganciclovir and valganciclovir in an infant with nephrotic syndrome associated with cytomegalovirus infection.Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients.Limited sampling strategy using Bayesian estimation for estimating individual exposure of the once-daily prolonged-release formulation of tacrolimus in kidney transplant children.Optimizing micafungin dosing in children.Population pharmacokinetics and dosing optimisation of ceftazidime in infants.Determination of cefoperazone and sulbactam in serum by HPLC-MS/MS: An adapted method for therapeutic drug monitoring in children.Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug.Pharmacogenetics of post-transplant diabetes mellitus in children with renal transplantation treated with tacrolimus.Population pharmacokinetics of cefotaxime and dosage recommendations in children with sickle cell disease.Penetration of cefotaxime into cerebrospinal fluid in neonates and young infants.[Dosing regimens of antibiotics in neonates: Variations in clinical practice and what should be done?].The importance of knowing how vancomycin is measured when interpreting its pharmacokinetic results.Individualization of valganciclovir prophylaxis for cytomegalovirus infection in pediatric kidney transplant patients.
P50
Q28272907-0D0A81D8-5DFF-485F-AEE8-B6523FB07CD1Q28542785-5AB9302B-44BB-4E3D-A40B-7968B32B3617Q30844731-251BA9FE-C585-4870-A140-9E39AA56BDCBQ33703969-7A2F4B2B-0C2E-4A9C-BABB-A9D56CE64C46Q33764995-79EC2696-5C57-446E-9FB7-86FBE1443553Q33797950-FEFAB08B-1036-42FB-84EE-4919739E17ECQ34596303-33FD0EB0-C72D-45B0-A6D3-15C9285584B5Q34700914-2E0E25C1-D6BE-4930-9680-094297059A13Q35219662-A2081BBB-35E4-4304-9B14-40C504FF3A38Q35846113-5CC92F43-39F3-4AB7-8FE7-61A7EFCD498BQ36036400-4643A422-442A-497E-B9A7-6164C81DC835Q36243693-FB47D205-FDC1-4825-9A62-55FBEE6F67B9Q36684184-55988619-DBF7-4F62-85C8-F54F55D091BBQ36729959-A0E59F47-F162-4372-93D3-E84FADB071C4Q36730100-5F5C28ED-DA3E-48DE-B2A8-6F475BE6A0DFQ37358644-C42FC4B6-30D0-46B5-8076-6593130430C2Q37731863-87844CF9-9107-4169-AE6C-444D9BCFB195Q37808608-82774FD0-5037-4387-8E97-C0C200658747Q38058654-18BAB869-AF73-411F-9025-3931293193F7Q38569678-B6CAC214-4086-402C-92E2-0CD900D2D50FQ38707591-9EB7F303-104E-4427-8727-568632BE3474Q39051618-D7898268-9356-4D54-B512-AB96B18C2DDCQ40848375-A5F56602-3A33-489F-B37A-4942D253207EQ40886900-3CB0F4A8-FEF1-40D4-9F42-F10EC5398CDFQ41516160-9D39B8FF-5FF5-4207-8B4D-237534120B5DQ42282104-BCED89AC-D713-47A5-8265-6A2FD7A2BD44Q43253108-9E71F060-EDD3-4705-AAB0-784E21561194Q45169061-65D8548C-32F0-4662-9075-B4471C1F7263Q45946480-8846BF9E-FEBA-4644-A9E3-C9E0C68DA3F8Q46121158-F2EE042C-97FE-4A73-9BEF-28278D5E3D04Q47563407-A079F938-19C7-44AA-A4C6-3242626162A6Q47645055-6A8ED2FA-188B-4559-90CE-BB84CA86B819Q47792817-5AC698CB-E36E-41F8-8A96-23A3CA0F525FQ48151911-846C1E89-22AD-4A60-ACD4-75EC7EB5AAF0Q49331510-06822D05-89FE-4F8F-AA90-02C76BA77ADBQ49598847-E8C582BB-ADAF-4300-8EE1-0138CF266680Q50044338-4C7D81AF-5057-4662-8353-1752EBEDD0F6Q50496366-C4468B8B-8144-469D-A754-3418D8481383Q50996835-B2552586-71D9-4176-9324-ED2539A6288FQ51383350-8E2D31AF-3B1B-437F-8460-8F374459E5C0
P50
description
researcher ORCID: 0000-0002-1830-338X
@en
name
Wei Zhao
@ast
Wei Zhao
@en
Wei Zhao
@es
Wei Zhao
@nl
Wei Zhao
@sl
type
label
Wei Zhao
@ast
Wei Zhao
@en
Wei Zhao
@es
Wei Zhao
@nl
Wei Zhao
@sl
prefLabel
Wei Zhao
@ast
Wei Zhao
@en
Wei Zhao
@es
Wei Zhao
@nl
Wei Zhao
@sl
P106
P31
P496
0000-0002-1830-338X